Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00437372 · ClinicalTrials.gov registry record · Phase 1

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

A Phase 1 study of Cancer and Head and Neck Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

Completed
Registry status
Phase 1
Development phase
39
Enrollment target
1
Study location

NCT00437372 is a Phase 1 study of Cancer and Head and Neck Cancer that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 39 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00437372, a Phase 1 study of Cancer and Head and Neck Cancer, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

COMPLETED
Registry status
Phase 1
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.

Interventions

  • RADIATION External Beam Radiation Therapy
  • DRUG Sunitinib

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2007-03
Est. Completion 2010-12
Phase Phase 1

What the Registry Record Tells You About NCT00437372

The ClinicalTrials.gov registry entry for NCT00437372 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which External Beam Radiation Therapy is the first listed.

NCT00437372 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00437372 about?

NCT00437372 is a clinical study titled "Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients". This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.

What is the current status of trial NCT00437372?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2007-03. Estimated completion is 2010-12.

What conditions does trial NCT00437372 study?

This clinical trial studies the following conditions: Cancer, Head and Neck Cancer, Pelvic Cancer, Thoracic Neoplasms, Nervous System Neoplasms.

What interventions are being tested in trial NCT00437372?

The interventions under investigation include: External Beam Radiation Therapy (RADIATION), Sunitinib (DRUG).

Who is sponsoring clinical trial NCT00437372?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00437372 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.